Celcuity (CELC) AI Stock Analysis

• Market Cap: $1.92B
• Dividend Yield: N/A
• Average Volume (3M): 908.05K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.26
• Revenue Growth: N/A
• EPS Growth: -25.61%
• Country: US
• Employees: 87
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.04
• Shares Outstanding: 42,426,712
• 10 Day Avg. Volume: 907,303
• 30 Day Avg. Volume: 908,049
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.27
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -16.52K
• Enterprise Value/Ebitda: -4.38
• 1Y Price Target: $76.33
• Price Target Upside: 54.45% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 9

• Rating: 44 Neutral
• Price Target: ―

Celcuity's stock score of 43.73 reflects the challenges faced by early-stage biotech firms. The company's financial performance is weak due to lack of revenue and high expenses. Technical analysis shows a neutral to slightly negative outlook, while valuation metrics are poor due to negative earnings. Despite these challenges, the earnings call provided a positive outlook with potential future revenue and strong financial positioning. The overall score indicates significant risks but potential for future growth if clinical and financial milestones are achieved.

Positive Factors

FDA Application Acceptance

The FDA's acceptance of the NDA for gedatolisib under the Real-Time Oncology Review program is a significant milestone. It suggests regulatory confidence in the drug's potential, which could expedite market entry, enhancing Celcuity's competitive position and revenue prospects.

Strong Financial Position

A robust cash position provides Celcuity with the financial flexibility to fund ongoing R&D and clinical trials without immediate pressure to raise additional capital. This stability supports long-term strategic initiatives and potential growth opportunities.

Potential Blockbuster Revenue

The potential market size for gedatolisib, if approved, represents a significant revenue opportunity. This aligns with Celcuity's strategy to leverage its diagnostic platform for high-impact treatments, potentially transforming its financial outlook and market position.

Negative Factors

Consistent Losses

The increasing net loss highlights ongoing financial challenges, primarily due to high R&D and operational expenses. This trend underscores the risk of prolonged unprofitability, which could strain resources and delay breakeven, impacting long-term financial health.

High R&D Expenses

Rising R&D costs reflect the intensive investment required for clinical trials and product development. While necessary for innovation, these expenses can pressure margins and cash flow, posing a risk if not offset by future revenue growth.

Lack of Revenue

The absence of revenue generation is a critical concern, as it limits Celcuity's ability to self-fund operations. This reliance on external financing increases vulnerability to market conditions and investor sentiment, potentially affecting long-term viability.

Celcuity Business Overview & Revenue Model

Company Description

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, and advanced or metastatic breast cancer. The company is also developing CELsignia MP test, a qualitative laboratory developed test that measures HER2, c-Met, and PI3K signaling activity in breast and ovarian tumor cells. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was founded in 2011 and is headquartered in Minneapolis, Minnesota.

How the Company Makes Money

Celcuity generates revenue primarily through the commercialization of its CELsignia platform. The company's revenue model is based on partnerships with pharmaceutical companies and healthcare providers who utilize its diagnostic tests to optimize cancer treatment strategies. Celcuity collaborates with pharmaceutical firms to enhance the efficacy of their targeted therapies, potentially sharing in the economic benefits of improved treatment outcomes. Additionally, the company may receive payments for conducting clinical trials and providing diagnostic services to institutions focused on personalized cancer treatment.

Celcuity Financial Statement Overview

Summary

Celcuity's financial performance reflects the challenges of early-stage biotech firms. The income statement shows consistent losses with no revenue, leading to a score of 10. Despite a stable balance sheet with low debt and strong liquidity, the declining equity is a concern, resulting in a score of 40. Persistent negative free cash flow due to high cash burn further impacts the score, with cash flow scoring 30. Overall, financial stability is challenged by high operational expenses and no revenue generation.

Income Statement

Celcuity's income statement shows consistent losses with no revenue generation over multiple years, which is common in biotech firms during early stages. The company has high negative EBIT and net income, reflecting significant R&D and operational expenses without revenue offset. The lack of revenue growth and profitability margins poses a challenge to financial stability.

Balance Sheet

The balance sheet indicates a stable equity base and low debt levels, with a debt-to-equity ratio of 0.002 in 2024. The company has substantial cash reserves compared to its liabilities, indicating a strong liquidity position. However, the declining equity and increasing liabilities over time can be a concern if the trend continues without revenue growth.

Cash Flow

The cash flow statement reveals persistent negative free cash flow, indicating high cash burn due to operational activities. However, the company has managed to secure financing, as shown by strong positive financing cash flows, which provide necessary liquidity. The free cash flow to net income ratio remains negative, highlighting inefficiencies in cash generation relative to net losses.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-31.11K	-129.95K	-142.77K	-210.92K	-303.24K	-385.59K
EBITDA	-117.32M	-101.37M	-58.31M	-39.18M	-28.05M	-9.17M
Net Income	-127.16M	-111.78M	-63.78M	-41.35M	-30.56M	-9.09M
Balance Sheet
Total Assets	218.13M	245.12M	191.22M	175.70M	85.91M	12.96M
Cash, Cash Equivalents and Short-Term Investments	205.69M	235.10M	180.58M	168.59M	84.29M	11.64M
Total Debt	98.71M	97.95M	37.45M	35.24M	14.89M	262.49K
Total Liabilities	131.46M	129.50M	51.45M	41.93M	17.20M	1.25M
Stockholders Equity	86.67M	115.62M	139.77M	133.77M	68.71M	11.70M
Cash Flow
Free Cash Flow	-66.62M	-83.72M	-53.91M	-36.17M	-20.39M	-7.24M
Operating Cash Flow	-66.40M	-83.47M	-53.81M	-36.01M	-20.31M	-7.15M
Investing Cash Flow	-42.34M	-63.07M	-5.01M	-144.03M	-81.40K	-89.37K
Financing Cash Flow	129.86M	138.39M	64.91M	120.33M	93.04M	137.97K

Celcuity Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 49.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CELC, the sentiment is Positive. The current price of 49.42 is below the 20-day moving average (MA) of 53.47, below the 50-day MA of 49.51, and above the 200-day MA of 21.00, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 49.45 is Neutral, neither overbought nor oversold. The STOCH value of 37.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CELC.

Celcuity Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALT	52 Neutral	$341.56M	-3.34	-54.38%	―	-95.11%	27.25%
ABVX	49 Neutral	$6.49B	-27.41	-434.26%	―	―	18.47%
RAPP	44 Neutral	$1.32B	-11.59	―	―	―	―
CELC	44 Neutral	$1.92B	―	-134.54%	―	―	-25.61%
ORIC	43 Neutral	$1.14B	-5.98	―	―	―	-7.33%
AUTL	41 Neutral	$428.49M	-1.88	-51.64%	―	187.52%	26.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%